Botulinum Toxin — The Dose-Response Relationship and What It Means for Clinical Practice

Does having a bigger dose of Botox make it last longer?

Every prescription medicine has a dose-response relationship, the principle that the biological effect of a drug varies predictably with the amount administered. In most of medicine, this relationship is fundamental to clinical decision-making: too little produces no meaningful effect, too much produces toxicity, and the therapeutic window between the two is where good clinical practice operates.

Botulinum toxin is no different. And yet the dose-response relationship in aesthetic Botox practice is rarely discussed with the rigour it deserves. This is partly because the consequences of under-dosing are commercial rather than harmful, and partly because the relationship between dose, effect, and duration is more nuanced than a simple linear model would suggest. Understanding it properly how the treatment should be planned, delivered, and followed up.

The most clinically important aspect of the botulinum toxin dose-response curve is the existence of a threshold below which the clinical effect is negligible.Botulinum toxin acts by blocking the release of acetylcholine at the neuromuscular junction, but the neuromuscular junction has a considerable safety margin.

Under normal physiological conditions, a motor nerve terminal releases considerably more acetylcholine than is needed to trigger muscle contraction. This redundancy means that partial blockade of acetylcholine release, by a sub-therapeutic dose of toxin, may produce no clinically visible effect at all, because the remaining unblocked junctions continue to release sufficient neurotransmitter to sustain contraction.

The practical implication is that there is a minimum effective dose below which the patient simply does not respond and that the dose required to cross that threshold varies considerably between patients depending on muscle mass, muscle strength, and individual in neuromuscular junction density. A practitioner who applies a fixed low dose to every patient without clinical assessment is not treating some patients conservatively. They are not treating some patients at all.

Above the therapeutic threshold, the relationship between dose and duration is well documented. Patients can expect treatments to last three months or more, but often as many as four to five months depending on the facial area, dose, and formulation. Repeated toxin treatments may prolong duration of effect or potentiate the effect.

The dose-duration relationship has been examined directly in clinical trials with compelling results. A phase II randomised controlled trial found that 40 units of prabotulinumtoxinA, twice the approved standard dose, produced a median duration of effect of 183 days, compared to 149 days for the standard 20 unit dose. In this pilot study, the higher dose was observed to be safe and produced a duration of approximately six months.

This finding, that doubling the dose extends by approximately a third illustrates a key feature of the dose-duration curve: it is not linear. Beyond the threshold, increasing the dose produces progressively smaller increments in duration. There is a ceiling effect, and administering very high doses produces diminishing returns in terms of duration while increasing the risk of complications.

The relationship between dose and duration also varies by anatomical area. Factors that may influence the duration of action of botulinum toxin include the association of toxins with accompanying proteins, which can affect neuromuscular receptors, as well as the emotional expression through gesticulation, toxin reconstitution, and the injection performed.

Areas of high muscular activity, the frown lines in a habitual frowner, the crow's feet of someone who smiles frequently and are subject to accelerated recovery of function compared to areas of lower activity. The dose required to achieve equivalent duration in high-activity areas is therefore greater than in ones.

The consequences of under-dosing in aesthetic botulinum toxin practice are predictable and well recognised by experienced practitioners, even when they are rarely stated openly. A sub-therapeutic or marginally therapeutic dose produces a result that is partial, uneven, and short-lived. The patient notices that lines have softened incompletely, that movement persists in areas where it should have been relaxed, and that the result begins to fade noticeably than expected.

This poor result has a clinical cause, inadequate dose relative to the individual patient's muscle mass and threshold, and a commercial context. A clinic that prices botulinum toxin treatment at the lower end of the market must, by financial necessity, keep product costs proportionately low. Since the product cost is directly related to the amount used, a low-price treatment is structurally incentivised towards under-dosing.

The receives less product than they need, experiences a disappointing result, and may be told at follow-up that they do not a top-up because honouring the top-up convention at the original price would whatever margin the treatment was generating.

The top-up exists in responsible aesthetic practice precisely because the dose-response relationship makes it necessary. A first treatment should be calibrated conservatively. Particularly in a new patient whose muscle strength and individual response have not yet been characterised with the explicit intention of assessing the result at two weeks and supplementing where clinically indicated. A clinic that declines to honour this convention is not simply cutting corners on aftercare. It is failing to complete the clinical episode that the treatment requires.

The dose-response relationship does not operate uniformly across patients. Individual variation in muscle mass, muscle strength, neuromuscular density, and metabolic rate all influence both the threshold dose required for clinical effect and the duration of that effect once .

Primary non-response to botulinum toxin refers to individuals who show an innate insensitivity to the toxin upon initial exposure, without prior treatments or antibody development. Non-response or resistance has become an increasingly significant concern, particularly since younger patients who are increasingly opting for aesthetic procedures accumulate greater total toxin doses over their lifetime.

This individual variation is the clinical argument against standardised treatment templates. That is, fixed injection points at fixed doses applied identically to every patient. Such templates may have been developed and validated in relatively study populations, and may perform adequately in patients whose anatomy closely resembles that population.

However, they perform poorly in patients whose muscle anatomy, strength, or compensation patterns differ from that template. This is frequently the case in older patients, in patients with asymmetry, and in who have developed compensatory muscle activity in response to the age-related changes we have written about elsewhere in this blog.

A clinical assessment should precede ever botulinum toxin treatment. It should include, at minimum :

an evaluation of the resting position and dynamic movement of the relevant muscles,

an assessment of compensation patterns — in the forehead and around the eye

a judgement about the relative muscle mass being treated.

This assessment informs the dose and the placement. Without it, the practitioner is not the patient. They are treating a template of a patient and the results, as many patients have discovered, are correspondingly imprecise.

A consideration that is rarely discussed in aesthetic botulinum toxin practice, but that has genuine long-term clinical implications, is the relationship between cumulative dose and immunogenicity. This is the risk of neutralising antibodies that reduce or eliminate the clinical to future treatment.

Secondary non-response is a phenomenon in which botulinum toxin is effective at onset but becomes ineffective later. Factors contributing to this include antigenicity, commercial presentation, clinical practice, Hormone Replacement Therapy (HRT/BHRT) and patient lifestyle.

While the risk of clinically significant antibody formation at cosmetic doses is low, it is not zero and it is related to the total protein load delivered with each and the of treatments. This is one of the arguments for using the minimum effective dose rather than defaulting to higher doses as a routine strategy for extending duration: the long-term protection of the patient's immunological response to treatment is a clinical consideration that deserves more attention than it typically receives.

The advent of purer toxin formulations such as Bocouture (Xeomin), which contains no complexing proteins was partly motivated by the theoretical reduction in immunogenic stimulus compared to formulations containing accessory proteins. Whether this translates into a meaningful clinical difference in antibody formation rates at cosmetic doses remains debated, but the principle of minimising unnecessary protein load is sound.

The dose-response evidence supports a clinical approach to botulinum toxin that is individually calibrated, conservatively initiated, and properly completed at follow-up.

The appropriate starting dose is determined by clinical of the individual patient — their muscle mass, their movement patterns, their compensation behaviours, and any relevant history of previous treatment and response. It is not determined by a price point or a template.

The follow-up appointment at two weeks is not optional. It is the second half of a clinical episode that cannot be properly completed without it. The result is assessed, the brow and eye position examined, and supplementary product administered where it is both needed and safe. This is how responsible botulinum toxin practice works and the dose-duration science is one of the reasons why.

The views expressed in Clinical Perspectives are the Dr Forrester’s own and reflect his personal and professional experience of over 25 years in medicine.

References

Hexsel D et al. Botulinum toxin: examining duration of effect in facial applications. DARE Database of Reviews. NCBI Bookshelf. 

Fagien S et al. Safety and Duration of Effect of 40-Unit for the Treatment of Moderate to Severe Glabellar Lines. Aesthetic Surgery Journal. 2024. 

Alcolea J, Monforte F. Controversies about botulinum toxin type A effect. Aesthetic Medicine.2025;11(1). 

Feighelstein MEB. Duration of botulinum toxin effects: Determining factors and practical recommendations. PMFA Journal.  2025. 

Exploring Nonresponse to Botulinum Toxin in Aesthetics. JMIR Dermatology. 2025. 

Filler-Induced Vascular Occlusion

Why Botox Treatments Last Longer Over Time

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Doctors
Company Ltd
Company no.